Skip Navigation Archive: U.S. Department of Health and Human Services U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archival print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

December 4, 1998: Steven Teutsch, Merck & Co., Inc.

Response to AHRQ on CERTs

Responses received to a call for ideas and study topics for implementation of AHRQ's new demonstration program for grants to establish Centers for Education and Research on Therapeutics (CERTs).

I have some suggestions:

  • Encourage collaboration with and funding from providers and industry: with providers to facilitate access to patients and clinical data which may be important for studies and to demonstrate methods, and with industry since we have legitimate interests in the appropriate use of pharmaceutical agents and have expertise. Centers should consider how large existing databases can be used—this would require identifying the necessary data elements and data sets which contain them.
  • Add research component on adherence/compliance by patients and providers. This would include research to increase adherence to guidelines and development of theory and practice of enhancing compliance. This should be directly linked to demonstrations of effectiveness in real-world situations. The focus as written is on traditional Food and Drug Administration (FDA) interests of safety and efficacy, including misuse of pharmaceuticals, interactions, etc. While appropriate, estimates of underutilization are equally important.
  • Add research component on guideline development for pharmaceutical agents, implementation and evaluation of programs to increase appropriate use of pharmaceutical agents.
  • Add research component on alternative medications. These are in wide-spread and increasing use and information is desperately needed about efficacy, effectiveness, safety and interactions with other medications. FDA has little jurisdiction over these products, yet their consequences are poorly understood. Among the issues: are these products used in addition to pharmaceuticals, do they substitute for them, does their use lead to delay in seeking effective medication, does their use avoid unnecessary visits and use of pharmaceuticals?
  • Models of organization of the Centers: The Centers for Disease Control (CDC) has models which may be appropriate, e.g., injury centers, prevention centers, urban research centers.

Steven Teutsch
Outcomes Research and Management
PO Box 4, WP39-169
Merck & Co., Inc.
West Point, PA 19486-0004
Telephone: (215) 652-2788
Fax: (215) 652-0860
E-mail: steven_teutsch@merck.com

Disclaimer and Copyright

Return to Responses to AHCPR on CERTs

Current as of October 2012
Internet Citation: December 4, 1998: Steven Teutsch, Merck & Co., Inc.: Response to AHRQ on CERTs. October 2012. Agency for Healthcare Research and Quality, Rockville, MD. http://archive.ahrq.gov/policy/foia/certs/cert7.html

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care